Our results show the potential of this cDC1-based vaccine to be combined with standard anti-PD-1 therapy [54] or used in anti-PD-1 resistant tumors, inducing both effector and long-lasting anti-tumor CD8+ and CD4+ T cell responses. The gene discussed is CD4; the disease is neoplasm.